[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"growth--development\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:growth--development":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,103,144,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100626268","phase-2-the-impact-of-shigellosis-and-recommended-treatment-in-children-100626268",false,"NCT07433426","The Impact of Shigellosis and Recommended Treatment in Children","TrtNDSD","Inclusion Criteria:\n\n* Patients \\>6 and ≤59 months of age seeking care in the study hospitals\n* Patients residing within the study catchment area\n* Present with watery diarrhea and positive for Shigella by RLDT\n* Willing to be available for sample and data collection during the follow up visits\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant's parent\u002Fguardian to give written informed consent or comply with study protocol\n* Diarrhea started more than 96 hours before enrollment\n* Antibiotics related to shigellosis treatment (including the investigational drug azithromycin) taken in the past 5 days\n* More than 2 doses of antidiarrheal drugs taken in the past 24 hours\n* History of allergy to Azithromycin\n* Presence of visible blood in stool\n* Children with severe acute malnutrition (below -3z scores of the median WHO growth standards).\n* History of congenital heart diseases, known gastrointestinal abnormalities, including short bowel syndrome, chronic (inflammatory or irritable) bowel disease, inherited or acquired immune system deficiency rendering the patient immunocompromised, including chronic\u002Flong-term steroid treatment or other immunosuppressive treatment\n* Fever over 39°C (102°F) with other complications that require antibiotic treatment\n* Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study","ALL","6 Months","59 Months",{"count":20,"type":21},700,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate whether antibiotic treatment of non-dysentery Shigella associated watery diarrhea (NDSD) cases improves clinical outcomes and growth in children.\n\nChildren with NDSD seeking care for diarrhea at the study hospitals in Bangladesh and Zambia will be enrolled and randomized to receive Azithromycin or placebo (a look-alike substance that contains no drug). Enrolled children will be followed for three months with household visits.\n\nThe investigators will determine whether antibiotic treatment of NDSD reduces the duration of diarrhea and time to microbiological cure (shedding of Shigella in stool), and whether it improves growth in children compared with the placebo group.",[27,28,29],"Diarrhea Infectious","Shigella","Growth & Development",[31,32,33,34,35,36,37],"shigella","children","randomized clinical trial","weight for age","growth outcomes","Azithromycin","Diarrhea","RECRUITING","2026-03-27",{"date":41,"type":42},"2026-03-30","ACTUAL",{"date":44,"type":42},"2026-03-18",{"date":46,"type":21},"2030-08",{"name":48,"class":49},"Johns Hopkins Bloomberg School of Public Health","OTHER",4,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":80,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":50},"100628121","breastmilk-and-the-link-to-overweightobesity-and-maternal-diet-in-the-mother-breastmilk-child-triad-100628121","NCT07457515","Breastmilk and the Link to Overweight\u002FObesity and Maternal Diet in the Mother-breastmilk-child Triad","Analysis of the Transmission of Overweight\u002FObesity in the Mother-breastmilk-child Triad in Relation to Maternal Cardiometabolic Status and Diet","BLOOM-Triad","Inclusion Criteria:\n\nfor mother:\n\n* at least 19 years,\n* plan of exclusively or predominantly breastfeeding for 6 months,\n* consent to a sampling of biological material and participate in all planned procedures (for both mother and infant),\n* willingness to finish the follow-up,\n* well-understanding of the Polish language (for non-Polish nationalities); for infants:\n* 1 month or less,\n* clinically healthy,\n* none or one formula feeding per day\n\nExclusion Criteria:\n\nfor mother:\n\n* type 1 or 2 diabetes diagnosed before pregnancy,\n* uncontrolled thyroid disease,\n* breastfeeding more than 1 child or being a milk donor,\n* tobacco\u002Falcohol use during pregnancy or currently,\n* inability to express a sufficient amount of milk; for infants:\n* congenital disease,\n* birth from a multiple pregnancy,\n* preterm birth (\\\u003C37 Hbd).",true,"FEMALE","19 Years",{"count":63,"type":21},165,"OBSERVATIONAL","The prospective 5-month follow-up study will involve 150 mother-infant dyads grouped based on maternal baseline BMI category (normal weight, overweight, obesity). The investigators plan 3 study visits (1, 3, and 6 months postpartum) with analysis the following parameters and outcomes:\n\n1. maternal anthropometry and body composition;\n2. maternal dietary intake and dietary patterns (with results of biomarker-based validation);\n3. maternal status of lipophilic antioxidants, selected vitamins, and fatty acids profile that may be related to adipose tissue metabolism, inflammation, and cardiometabolic status;\n4. maternal metabolomics, adipokines, insulin, selected biomarkers of inflammation, altered glucose metabolism, and oxidation;\n5. breastmilk composition assessed by systemic approach (macronutrients, fatty acids profile, lipophilic antioxidants, adipokines, hormones, immunological profile, and preliminary lipidomic analysis in part of the study group);\n6. infant growth trajectory, body composition, urine metabolomics, and biomarkers of oxidative stress.\n\nAdditionally, maternal and infant stool, buccal swabs, and human milk samples will be banked for further microbiome analysis studies.",[67,68,69,70,71,29,72,73,74,75,76,77,78,79],"Body Weight","Obesity & Overweight","Human Milk\u002FBreastfeeding","Body Composition","Maternal Cardiometabolic Health","Metabolomic Profile","Infant Body Composition and Metabolism","Carotenoid Status","Fatty Acid Status","Immunologic Markers","Adipokines","Inflammation Biomarkers","Vitamin E",[81,82,83,84,77,85,86,87,88,89,90,91,92],"Lactation","Body composition","Infant development","Diet","Carotenoids","Fatty acids","Metabolomics","Inflammation","Oxidative stress","Overweight","Obesity","Tocopherols","NOT_YET_RECRUITING","2026-03-02",{"date":96,"type":42},"2026-03-09",{"date":98,"type":21},"2026-02",{"date":100,"type":21},"2029-09",{"name":102,"class":49},"Warsaw University of Life Sciences",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":60,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":127,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100616738","effectiveness-of-a-counseling-program-on-exclusive-breastfeeding-rates-in-a-primary-care-center-100616738","NCT07309510","Effectiveness of a Counseling Program on Exclusive Breastfeeding Rates in a Primary Care Center","Effectiveness of a Counseling Program on Exclusive Breastfeeding Rates in a Primary Care Center in A Coruña.Randomized Controlled Clinical Trial","ALM-AP","Inclusion Criteria:\n\n* Mothers who express a desire to breastfeed during a follow-up consultation with the Obstetric and Gynecological Nursing specialist at 36 weeks of gestation.\n* Mothers who plan to give birth at HMI of CHUAC, referred from the C.S. Ventorrillo.\n* Women who are fluent in Spanish or Galician.\n\nExclusion Criteria:\n\n* Maternal age under 18 years - Maternal use of drugs or medication that prevent breastfeeding .\n* Maternal infection with HIV or Human T-cell Leukemia Virus.\n* Mothers of newborns with cow's milk protein allergy, galactosemia, or congenital primary lactase deficiency.","18 Years",{"count":113,"type":21},160,[115],"NA","Introduction: Evidence supports that exclusive breastfeeding (EBF) is the most beneficial method of infant feeding up to 6 months of age. The practice confers numerous advantages for the infant and the mother. Many breasfeeding are abandoned early due difficulties experienced after dischargue and after returning to work. Development specific early breastfeeding support programs in the community is necessary to avoid unwanted abandonment.\n\nObjective: To analyse the differences in BF rates at six month of birth in healthy full-term newborns between the study groups.\n\nMethodology: Pilot study of a randomised clinical trial carried out in a Paediatric Nursing clinic at the Ventorrillo Health Centre in A Coruña. The study population will be mothers of healthy full-term newborns who wish to give BF at the time of delivery and whose reference health centre is the one of the study. The mother- newborn dyads in the control group (CG) will receive the usual care described in the child health Program of the Galician Health Service, and the dyads included in the intervention group (IG) will also receive specific advice on breastfeeding during the first 6 months of life. A study sample of 80 participants is estimated for each group. The study will be approved by the Research Ethics Committee of A Coruña-Ferrol. The variables under study will be collected in a data collection notebook for later statistical analysis. A significant value of p \\\u003C 0.05 being considered.",[29,118,119,120,121,122,123,124,125,126],"Breastfeeding Satisfaction","Breastfeeding Consultancy Training","Breastfeeding Duration","Breastfeeding After Discharge From Hospital Following Childbirth, Yes\u002Fno","Breastfeeding, Exclusive","Breastfeeding Attitude","Breastfeeding Support System","Breastfeeding Rate","Breastfeeding Outcomes",[128,129,130,131,132,133],"Breastfeeding","Infant","Human Milk","Health Education","Primary Health Care","Postpartum Period","2026-01-07",{"date":136,"type":42},"2026-01-08",{"date":138,"type":21},"2026-01",{"date":140,"type":21},"2027-01",{"name":142,"class":49},"Fundacion Profesor Novoa Santos",1,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":59,"sex":16,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":143},"100432864","a-first-ever-research-collaboration-to-characterize-mri-measured-neural-flexibility-development-in-chinese-toddlers-100432864","NCT04916652","A First-ever Research Collaboration to Characterize MRI Measured Neural Flexibility Development in Chinese Toddlers","Inclusion Criteria:\n\n1. Written informed consent has been obtained from the parent\u002Flegally acceptable representative.\n2. Full-term birth (≥ 37 weeks and ≥ 2.5kg)\n3. Typically developing Children aged between 32-34 months (2 years 8 months to 2 years10 month of age) at enrolment\n4. Neurotypical development as assessed by interview\n5. No major risk factors for learning, neurologic, or psychiatric disorder as assessed by interview \\[defined as a diagnosed learning neurologic or psychiatric disorder in a first degree relative (e.g. parents, siblings)\\].\n6. Dietary requirement detailed below:\n\nS-26 GOLD or ULTIMA GUM--fed group:\n\nI. Daily consumption of S-26 GOLD or ULTIMA GUM for the last 60 days (2 months) II. Desire of the parent to continue feeding GUM during the course of the study\n\nCow's milk-fed group:\n\nI. Daily consumption of cow's milk or for the last 60 days (2 months) II. Desire of the parent to continue feeding cow's milk during the course of the study\n\nExclusion Criteria:\n\n1. Delayed birth ( \\> 41 weeks gestation) as reported in medical record\n2. Birth Weight \\\u003C 2500 g or small for gestational age (birth weight below the 10th percentile) or large for gestational age (birth weight above the 90th percentile) as reported in medical record\n3. History of neurological (e.g., head injury, epilepsy), psychiatric or developmental disorder in the toddler as assessed by interview\n4. History of diagnosed neurological (e.g., head injury, epilepsy), psychiatric or developmental disorder in parents or siblings, as assessed by interview\n5. In utero exposure to alcohol abuse or illicit substances as defined as diagnosis of current substance use disorder in the biological mother and guidelines set by the American College of Obstetricians and Gynecologists and the Royal College of Physicians\n6. Multiple birth as reported in medical record\n7. Complicated pregnancy (e.g., preeclampsia, gestational diabetes) as assessed by medical interview\u002F medical record\n8. Abnormal screening laboratory values and studies considered to be clinically significant in the opinion of the Investigator (e.g., metabolic disease screening, neonatal bilirubin)","32 Months","34 Months",{"count":153,"type":21},60,"The overall objective is to characterize the developmental characteristics of MRI measured neural flexibility, as an index of cognitive flexibility, in Chinese toddlers (32 to 42 months old).",[29,156],"Brain","2025-11-26",{"date":159,"type":42},"2025-12-03",{"date":161,"type":42},"2024-04-06",{"date":163,"type":21},"2027-02",{"name":165,"class":166},"Société des Produits Nestlé (SPN)","INDUSTRY",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":59,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":174,"targetDuration":176,"studyType":64,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":143},"100578499","human-microbiome-research-and-development-for-overcoming-pediatric-diseases-100578499","NCT06812091","Human Microbiome Research and Development for Overcoming Pediatric Diseases","Prediction and Treatment of Pediatric Diseases and Long-term Outcomes Through Microbiome and Multi-Omics Study by Life Cycle","Inclusion Criteria:\n\n* children (including newborns) who have obtained their consent from their guardians\n\nExclusion Criteria:\n\n* subjects who did not obtain consent",{"count":175,"type":21},500,"10 Years","Prediction and treatment of pediatric diseases and long-term outcomes through microbiome and multi-omics analysis by life cycle: We aim to demonstrate that a wide range of diseases are associated with gut microbiome dysbiosis and to investigate the subsequent recovery (restoration) or further deterioration of the gut microbiome over time. This study seeks to offer a novel perspective on changes in the gut microbiome, particularly in the context of the gut-lung and gut-brain axes.",[179,180,181,29],"Human Microbiome","Pediatrics","Disease","2025-02-01",{"date":184,"type":42},"2025-02-06",{"date":186,"type":42},"2022-01-01",{"date":188,"type":21},"2030-01-01",{"name":190,"class":49},"Hanyang University"]